Physician profile
Greg L Friedman
NPI 1275531543
$437,263.80
in general payments reported to CMS, 2019-2025
45 companies · $2,156 in 2025
The $2,156 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173K · 2020: $29K · 2021: $7,488 · 2022: $108K · 2023: $76K · 2024: $42K · 2025: $2,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Travel and Lodging: $19K · Food and Beverage: $11K · Consulting Fee: $9,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,302.50 |
| Travel and Lodging | $19,045.36 |
| Food and Beverage | $10,532.64 |
| Consulting Fee | $9,766.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $196,672.85 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $122,356.04 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $92,355.64 | 2019-2024 | Austedo Xr, Austedo |
| Bioxcel Therapeutics, INC. | $3,632.20 | 2023-2024 | Igalmi |
| E.R. Squibb & Sons, L.L.C. | $3,534.19 | 2024-2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $2,402.88 | 2019-2024 | Invega Sustenna, Spravato |
| Janssen Pharmaceuticals, INC | $1,818.49 | 2021-2024 | Invega Sustenna |
| Janssen Research & Development, LLC | $1,750.00 | 2020 | |
| Vanda Pharmaceuticals INC. | $1,713.27 | 2019-2025 | Fanapt, Hetlioz |
| Eisai INC. | $1,567.65 | 2020-2021 | |
| Abbvie INC. | $1,326.03 | 2021-2025 | |
| Almatica Pharma LLC | $928.21 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Alkermes, INC. | $789.86 | 2019-2023 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $724.79 | 2020-2024 | Rexulti |
| Alvogen INC | $700.00 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.